TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03336879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
Study: NCT02690935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LALERG
Description: Homeopathic drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01740791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally
Study: NCT02777983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video App
Description: The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
Study: NCT01740791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally
Study: NCT03468920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
Study: NCT00585390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA fish oil concentrate; DHA fish oil concentrate
Description: 3.2 grams for EPA 1.6 grams for DHA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil capsule
Study: NCT01475409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold In-Tube (QFT-GIT)
Description: Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
Study: NCT00503516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Description: 1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet of 160 mg of placebo b.i.d.
Study: NCT03810144

Intervention type: GENETIC
Intervention: Vectra MBDA Test
Description: Vectra Guided versus Usual Care
Study: NCT04307784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3
Description: VD3 (50.000 IU/week) for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3FA
Description: Omaga-3FA (300 mg/day) for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 and Omega-3FA
Description: VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention is given
Study: NCT02460445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinylestradiol
Description: 35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
Study: NCT03396861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Subconjunctival aflibercept
Study: NCT06642714

Intervention type: PROCEDURE
Group type: OTHER
Intervention: weaning by early non-invasive ventilation and progressive high flow oxygen therapy
Description: Step 1 Clinical stability was confirmed:~(1)Without organ failure;(2)Without sepsis;(3)Stable heart rate and blood pressure without use of vascular active drugs.~Step2 Reduce the support parameters of the ventilator gradually. Step3 SBT when the ventilator mode is pressure support ventilation(PSV),P+PEEP≤16cmH2O for 2 hours.~Step4~①Success of SBT: titrate based HFOT time-------connected with tracheostomy tube ,flow rate and FiO2 able to maintain oxygen saturation as assessed by pulse oximetry monitoring of at least 95%.HFOT was interrupted in cases of sighs or symptoms of distress such as oxygen desaturation, RR\>30bpm, HR\>130bpm,SBP\>180mmHg or \<90mmHg.The time was based HFOT time. When any of these conditions were present the patient was connected again to the ventilator with the same parameters before titration. The duration of SBT was increased progressively over the following day according to patient tolerance. Then gradually extending HFOT time daily according patient condition. Wh
Study: NCT02460445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinylestradiol
Description: 35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproterone Acetate
Description: 2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone Acetate
Description: 2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
Study: NCT03468920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Acetaminophen
Description: Acetaminophen PO 1000mg once pre-operatively
Study: NCT03094403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic Acid 15% topical gel
Description: Gel
Study: NCT03468920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PO Placebo
Description: PO placebo capsule compounded to match PO Acetaminophen capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Solution Placebo
Description: This will serve as the placebo for the IV Acetaminophen intervention
Study: NCT03873324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 compound
Description: IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
Study: NCT05418426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVR Dose 1
Description: Estradiol 80 ug/progesterone 4 mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVR Dose 2
Description: Estradiol 160ug/progesterone 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Reference
Description: estradiol 1mg/progesterone 100 mg
Study: NCT01851798

Intervention type: OTHER
Intervention: Home sleep test administered to all enrolled subjects

Intervention type: OTHER
Intervention: Home sleep test administered to all enrolled subjects
Study: NCT01066299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon®
Description: single dose of OXT (24 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inactive nasal spray
Description: single dose (24 IU)
Study: NCT03329131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: An Elasto gel™ frozen (4°C) glove and sock
Study: NCT02228330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block
Description: a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
Study: NCT04103814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium-cannabidiolic acid cream
Description: Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
Study: NCT01657331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
Study: NCT03873324

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsules
Study: NCT04467463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block by 0.25% levobupivacaine
Description: SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block by 0.25% levobupivacaine
Description: SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
Study: NCT02908620

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-A
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-A
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-CB
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-CB
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Two sprays CTY-5339-A
Description: Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Two sprays CTY-5339-A
Description: Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)
Description: A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)
Description: A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
Study: NCT02292394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Cognitive Behavioral Telephone Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Intervention Pleasant Activities
Study: NCT01657331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: (Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
Study: NCT05938569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair restoration
Description: The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
Study: NCT02868931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INPUT
Description: Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators.
Study: NCT02315976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propatyl Nitrate
Description: Propatyl nitrate 10mg administered orally, three times daily
Study: NCT00844428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Study: NCT04871633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days

Intervention type: DRUG
Group type: OTHER
Intervention: Conventional
Description: IV Steroids Antibiotics
Study: NCT04342546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaGray RILA Breast® test
Description: The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
Study: NCT00192478

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Medi-524
Description: IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
Study: NCT01254929

Intervention type: DEVICE
Intervention: F-18 PET bone scan
Description: Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.

Intervention type: DEVICE
Intervention: Tc-99m bone scan
Description: Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
Study: NCT03094403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finacea® (azelaic acid) Gel, 15%
Description: Gel
Study: NCT04871633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: IV Steroids Antibiotics
Study: NCT00788658

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet modifications
Description: Diet consultation
Study: NCT03094403

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel
Study: NCT02983565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent oxygen therapy system (iO2Ts)
Study: NCT04423783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)
Description: Confrontation with spiders via gamified app
Study: NCT02034565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT00581919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bort, Dex, and Dox with ALCAR
Description: Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
Study: NCT03277872

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy with GlideScope (GVL) Blade
Description: 1. st Laryngoscopy with GVL Blade~2. nd Laryngoscopy with MAC Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization
Study: NCT03293667

Intervention type: OTHER
Group type: OTHER
Intervention: Exploratory synovial fluid analysis
Description: An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
Study: NCT03277872

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy with MacIntosh (MAC) Blade
Description: 1. st Laryngoscopy with MAC Blade~2. nd Laryngoscopy with GVL Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization
Study: NCT04090606

Intervention type: OTHER
Intervention: FTC Method Smoking Regimen
Description: cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes

Intervention type: OTHER
Intervention: Massachusetts Method Smoking Regimen
Description: 45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes

Intervention type: OTHER
Intervention: Health Canada Intense Smoking Regimen
Description: 55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
Study: NCT03891446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Intraocular implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Intraocular implant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care treatment based on investigator's judgement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care treatment based on investigator's judgement.
Study: NCT04423783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)
Description: Confrontation with spiders via gamified app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-guided one-session online exposure therapy according to (Öst, 1989)
Description: Massed exposure therapy over the course of one single session, applied in a remote-online context

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-guided one-session online exposure therapy according to (Öst, 1989)
Description: Massed exposure therapy over the course of one single session, applied in a remote-online context
Study: NCT00788658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy